Antares Pharma Inc
NASDAQ:ATRS
Intrinsic Value
Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ATRS.
Fundamental Analysis
Balance Sheet Decomposition
Antares Pharma Inc
| Current Assets | 174.3m |
| Cash & Short-Term Investments | 67.2m |
| Receivables | 91m |
| Other Current Assets | 16.1m |
| Non-Current Assets | 83.2m |
| PP&E | 29.8m |
| Intangibles | 17.9m |
| Other Non-Current Assets | 35.6m |
| Current Liabilities | 58.9m |
| Accounts Payable | 17.1m |
| Accrued Liabilities | 36m |
| Other Current Liabilities | 5.9m |
| Non-Current Liabilities | 22.8m |
| Long-Term Debt | 18.2m |
| Other Non-Current Liabilities | 4.6m |
Earnings Waterfall
Antares Pharma Inc
|
Revenue
|
184m
USD
|
|
Cost of Revenue
|
-68.3m
USD
|
|
Gross Profit
|
115.7m
USD
|
|
Operating Expenses
|
-88.4m
USD
|
|
Operating Income
|
27.3m
USD
|
|
Other Expenses
|
18.9m
USD
|
|
Net Income
|
46.3m
USD
|
Free Cash Flow Analysis
Antares Pharma Inc
ATRS Profitability Score
Profitability Due Diligence
Antares Pharma Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Antares Pharma Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
ATRS Solvency Score
Solvency Due Diligence
Antares Pharma Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Antares Pharma Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ATRS Price Targets Summary
Antares Pharma Inc
Ownership
ATRS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ATRS Price
Antares Pharma Inc
| Average Annual Return | 19.87% |
| Standard Deviation of Annual Returns | 40.39% |
| Max Drawdown | -65% |
| Market Capitalization | 950.7m USD |
| Shares Outstanding | 170 852 000 |
| Percentage of Shares Shorted | 2.86% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. The company is headquartered in Ewing, New Jersey and currently employs 201 full-time employees. The firm is focused on the development and commercialization of pharmaceutical products and technologies. The firm develops, manufactures, and commercialize, for itself or with partners, therapeutic products using its drug delivery systems. The firm products include XYOSTED, NOCDURNA, Epinephrine Injection USP, Sumatriptan Injection USP, Makena and Teriparatide Injection. Its XYOSTED injection product for subcutaneous administration of testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. NOCDURNA is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate. Its Epinephrine Injection USP products is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients.
You don't have any saved screeners yet
